StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
AGEN

Agenus Inc.

AGEN Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$7.82
-0.09 -1.14%

Key statistics

from XBRL data in SEC filings
Market cap
$326M
Revenue (TTM)
$124M
Net income (TTM)
$62.5M
EPS (TTM)
$2.05
P/E ratio
3.8
Dividend yield
Free cash flow
-$77.2M
Cash
$35.0M
Total assets
$186M
Gross margin
52-week range
$2.71 – $8.70

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure; Other events Jul 13, 2026 8-K Entered a material agreement Jul 6, 2026 8-K Shareholder vote results Jun 23, 2026 8-K Director or officer change May 15, 2026 10-Q Quarter ended 2026-03-31 May 11, 2026 8-K Results of operations (earnings release) May 11, 2026 8-K Other events Mar 26, 2026 10-K Fiscal year ended 2025-12-31 Mar 16, 2026 8-K Results of operations (earnings release) Mar 16, 2026 8-K Completed an acquisition or disposition; Unregistered sale of equity; Regulation FD disclosure Jan 16, 2026 8-K Director or officer change Jan 14, 2026 8-K Entered a material agreement; Modified rights of security holders Jan 8, 2026 10-Q Quarter ended 2025-09-30 Nov 10, 2025 8-K Results of operations (earnings release) Nov 10, 2025 8-K Entered a material agreement; Took on a direct financial obligation Oct 9, 2025 8-K Other events Sep 23, 2025 10-Q Quarter ended 2025-06-30 Aug 11, 2025 8-K Results of operations (earnings release) Aug 11, 2025 8-K Shareholder vote results Jun 20, 2025 8-K Entered a material agreement; Regulation FD disclosure Jun 4, 2025 10-Q Quarter ended 2025-03-31 May 12, 2025 8-K Results of operations (earnings release) May 12, 2025 10-K Fiscal year ended 2024-12-31 Mar 17, 2025 8-K Results of operations (earnings release) Mar 11, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Feb 26, 2025 8-K Terminated a material agreement Feb 10, 2025 8-K Exit or disposal costs Dec 5, 2024 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Regulation FD disclosure Nov 27, 2024 10-Q Quarter ended 2024-09-30 Nov 12, 2024 8-K Results of operations (earnings release) Nov 12, 2024 8-K/A Director or officer change Nov 8, 2024 8-K Director or officer change Nov 5, 2024 8-K Results of operations (earnings release); Director or officer change; Other events Aug 8, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Terminated a material agreement Aug 2, 2024 8-K Director or officer change Jun 17, 2024 8-K Shareholder vote results Jun 14, 2024 8-K Completed an acquisition or disposition May 30, 2024 8-K Results of operations (earnings release) May 7, 2024 10-Q Quarter ended 2024-03-31 May 7, 2024